News Acelyrin, Inc.

Equities

SLRN

US00445A1007

Market Closed - Nasdaq Other stock markets 01:30:00 23/05/2024 am IST			5-day change	1st Jan Change
4.52 ^USD	+4.39%		-4.64%	-39.41%

22/05	HC Wainwright Adjusts Price Target on ACELYRIN to $18 From $16, Maintains Buy Rating	MT
09/05	Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on ACELYRIN to $18 From $16, Maintains Buy Rating	22/05	MT
Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024	09/05	CI
ACELYRIN, INC. Announces Leadership Transition	09/05	GL
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones	09/05	GL
Acelyrin, Inc. Announces CEO Changes	09/05	CI
Acelyrin, Inc. Announces Leadership Transition	09/05	CI
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024	30/04	GL
Affibody publishes Annual Report 2023	19/04	AQ
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	05/04	DJ
Acelyrin, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights	29/03	GL
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights	29/03	AQ
North American Morning Briefing : Stocks Struggle After New Records	22/03	DJ
Wells Fargo Raises ACELYRIN's Price Target to $13 From $11, Keeps Equalweight Rating	21/03	MT
Sector Update: Health Care Stocks Ease Late Afternoon	21/03	MT
Sector Update: Health Care	21/03	MT
Acelyrin Shares Rise After Lonigutamab Shows Clinical Responses in Thyroid Eye Disease Trial	21/03	MT
Transcript : Acelyrin, Inc. - Special Call	20/03
Acelyrin : Corporate Presentation	20/03	PU
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease	20/03	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Acelyrin, Inc.

Equities

SLRN

US00445A1007

Summary

Filters